Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	120377
Country	Italy

Category	Oncology
Manuscript Type	Systematic Reviews
Article Title	Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan–Meier curves of randomized trials
Manuscript Source	Invited Manuscript
All Author List	Vera Damuzzo, Stefano Vecchia, Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, Elena Orlandi and Andrea Messori
Funding Agency and Grant Number
Corresponding Author	Andrea Messori, Osservatorio Innovazione Section, HTA Regione Toscana, via Alderotti 26/N, Firenze 50139, Italia, Italy. andrea.messori@osservatorioinnovazione.net
Key Words	Hepatocellular carcinoma; Immune checkpoint inhibitors; Tyrosine kinase inhibitors; Indirect comparison; Overall survival
Core Tip	In the absence of head-to-head trials for first-line unresectable hepatocellular carcinoma, we reconstructed individual patient data from eight phase III trials to indirectly compare immune checkpoint inhibitor and tyrosine kinase inhibitor combinations. Most regimens outperformed sorafenib, with camrelizumab plus rivoceranib emerging as the most effective option, demonstrating superiority over tremelimumab plus durvalumab and anlotinib plus penpulimab. Restricted mean survival time analyses revealed revealed that nivolumab plus ipilimumab, lenvatinib, and pembrolizumab plus lenvatinib achieved results similar to those of camrelizumab plus rivoceranib. These findings provide a practical framework for treatment positioning and underscore the critical influence of comparator on estimated efficacy.
Citation	Damuzzo V, Vecchia S, Gasperoni L, Del Bono L, Ossato A, Orlandi E, Messori A. Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan–Meier curves of randomized trials. World J Gastrointest Pharmacol Ther 2026; In press

Received	2026-02-27 03:17
Peer-Review Started	2026-02-27 03:17
First Decision by Editorial Office Director	2026-04-15 08:59
Return for Revision	2026-04-15 08:59
Revised	2026-04-30 08:46
Publication Fee Transferred
Second Decision by Editor	2026-05-22 02:37
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-05-22 06:07
Articles in Press	2026-05-22 06:07
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2150-5349 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com